Acute Lymphoblastic Leukemia News and Research

RSS
Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells, the cells in the body that normally fight infections. There are two main types of white blood cells-lymphoid cells and myeloid cells. ALL affects lymphoid cells.
Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Penns' Abramson Cancer Center rated as 'exceptional' by NCI

Penns' Abramson Cancer Center rated as 'exceptional' by NCI

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

Researchers identify drugs that may enhance ability of TKI dasatinib to kill human cancer cells

Researchers identify drugs that may enhance ability of TKI dasatinib to kill human cancer cells

New NCCN Guidelines for Patients and NCCN Quick Guide for Kidney Cancer published

New NCCN Guidelines for Patients and NCCN Quick Guide for Kidney Cancer published

UT Southwestern, NASA to study zero-gravity effects on the human brain in cancer patients

UT Southwestern, NASA to study zero-gravity effects on the human brain in cancer patients

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

Detailed molecular analyses reveal new treatment options for aggressive childhood leukemia

Detailed molecular analyses reveal new treatment options for aggressive childhood leukemia

Discovery paves way for new therapeutic approaches to treat fatal leukemia in children

Discovery paves way for new therapeutic approaches to treat fatal leukemia in children

Research sheds light on new therapeutic options for acute lymphoblastic leukemia

Research sheds light on new therapeutic options for acute lymphoblastic leukemia

Damon Runyon creates new award to increase number of physician-scientists

Damon Runyon creates new award to increase number of physician-scientists

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Researchers track down key gene mutation responsible for causing acute lymphoblastic leukemia

Researchers track down key gene mutation responsible for causing acute lymphoblastic leukemia

Researchers identify potential treatment option for childhood leukemia

Researchers identify potential treatment option for childhood leukemia

US cancer physicians explore new approach to help older patients undergoing hematopoietic stem cell transplant

US cancer physicians explore new approach to help older patients undergoing hematopoietic stem cell transplant

Researchers report new way to treat T-cell acute lymphoblastic leukemia

Researchers report new way to treat T-cell acute lymphoblastic leukemia

Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Researchers submit patent application for drug that could destroy acute lymphoblastic leukemia

Researchers submit patent application for drug that could destroy acute lymphoblastic leukemia

Childhood cancer survivors more likely to be obese than healthy peers

Childhood cancer survivors more likely to be obese than healthy peers

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.